Skip to main content
ABION Inc. logo

ABION Inc. — Investor Relations & Filings

Ticker · 203400 ISIN · KR7203400007 KO Professional, scientific and technical activities
Open in API
Filings indexed 408 across all filing types
Latest filing 2024-12-16 Regulatory Filings
Country KR South Korea
Listing KO 203400

About ABION Inc.

https://abionbio.com/en/

ABION Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines, focusing on first-in-class and best-in-class therapeutics for oncology and viral diseases. The company's lead oncology asset is ABN401, a selective c-Met tyrosine kinase inhibitor (TKI) designed to treat non-small cell lung cancer (NSCLC) with MET mutations, which has shown a favorable safety profile. Another key pipeline candidate is ABN501, a novel monoclonal antibody targeting Claudin-3 for various cancers. Beyond oncology, ABION is developing ABN101, a second-generation Interferon-β formulated as a broad-spectrum anti-viral inhaler for respiratory infections. The company aims to commercialize its assets in global markets through internationally recognized clinical processes.

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for the purpose of determining shareholders eligible to vote at the upcoming 18th Annual General Meeting. It does not contain the full proxy materials or the meeting presentation itself, but rather serves as a formal regulatory notice of a corporate action. Given it is a standard regulatory disclosure regarding shareholder rights and meeting preparation, it fits best under the general regulatory filings category.
2024-12-16 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a 'Correction Report' (정정신고) regarding the granting of stock options (주식매수선택권 부여). It details changes to the number of shares granted to specific individuals due to resignations and updates the total share option status. In the context of Korean regulatory filings (DART), this type of disclosure regarding stock option grants and their subsequent amendments falls under general regulatory filings as it does not fit into specific categories like 'Director's Dealing' (which usually refers to market trades) or 'Share Issue' (which refers to capital changes). Therefore, it is classified as a Regulatory Filing (RNS).
2024-12-16 Korean
[기재정정]주식매수선택권부여에관한신고
Remuneration Information Classification · 100% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is specifically a '정정신고' (Amendment Report). It details changes to stock option grants, including the number of shares and the list of recipients. In the context of corporate filings, announcements regarding stock option grants, especially those involving amendments to previous filings, are classified as regulatory filings (RNS) as they do not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for capital changes).
2024-12-16 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Amendment Report) to a previously filed stock option grant. This type of filing relates to changes in capital structure and equity-based compensation, which falls under the category of 'Share Issue/Capital Change' (SHA) in the provided taxonomy, as it details adjustments to stock option grants and their impact on total issued shares.
2024-12-16 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Services Commission and Korea Exchange. This type of filing is a standard regulatory requirement in South Korea for major shareholders to disclose changes in their ownership stakes, including details on special relationships, collateral agreements, and shareholding purposes. Based on the provided categories, this falls under 'Major Shareholding Notification'.
2024-12-13 Korean
합병등종료보고서(자산양수도)
M&A Activity Classification · 100% confidence The document is a 'Report on the Completion of Merger, etc.' (합병등종료보고서) filed with the Financial Supervisory Service (금융감독원). It details the finalization of an asset acquisition (자산양수도) involving the exchange of shares (현물출자) between Abion Co., Ltd. and Telcon RF Pharmaceutical. Since this document reports the completion of a specific corporate transaction (M&A/Asset Acquisition) rather than a general regulatory announcement or a simple notice of publication, it falls under the M&A Activity category.
2024-12-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.